| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1112388649 |
| P356 | DOI | 10.1186/S12885-019-5385-Y |
| P932 | PMC publication ID | 6390545 |
| P698 | PubMed publication ID | 30808336 |
| P2093 | author name string | Tao Jiang | |
| Yanqiu Wang | |||
| Mingyan Jiang | |||
| Shuijing Gu | |||
| P2860 | cites work | MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma | Q73653083 |
| Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9 | Q82332973 | ||
| The TGF-beta superfamily cytokine MIC-1/GDF15: secretory mechanisms facilitate creation of latent stromal stores | Q83056445 | ||
| Research on values of GDF-15 level in the diagnosis of primary liver cancer and evaluation of chemotherapeutic effect | Q89289074 | ||
| MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily | Q24317134 | ||
| The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews | Q24801517 | ||
| GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective | Q26798142 | ||
| Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses | Q28131633 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer | Q33648690 | ||
| Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer | Q33723662 | ||
| Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma | Q34045939 | ||
| Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer | Q34577084 | ||
| Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer | Q35006757 | ||
| Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy | Q35051499 | ||
| MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma | Q35475302 | ||
| Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma | Q35634311 | ||
| Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality. | Q35998469 | ||
| Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer | Q37117179 | ||
| Interpretation of tests of heterogeneity and bias in meta-analysis | Q37329334 | ||
| Macrophage inhibitory cytokine-1: possible bridge molecule of inflammation and prostate cancer | Q37360803 | ||
| Guidelines for diagnostic tests and diagnostic accuracy in surgical research | Q37710081 | ||
| Macrophage inhibitory cytokine-1: a review of its pleiotropic actions in cancer | Q38065700 | ||
| Current and future biomarkers for pancreatic adenocarcinoma | Q38670577 | ||
| Cancer treatment and survivorship statistics, 2016. | Q38859236 | ||
| Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease | Q39071708 | ||
| Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer | Q39173145 | ||
| Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach | Q39772828 | ||
| Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers | Q40568605 | ||
| Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer? | Q43690125 | ||
| CXXC4 activates apoptosis through up-regulating GDF15 in gastric cancer | Q47158928 | ||
| Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass | Q47368220 | ||
| Growth/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer | Q50199824 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| biomarker | Q864574 | ||
| P577 | publication date | 2019-02-26 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis | |
| P478 | volume | 19 |
Search more.